Dr Chiara Cremolini talks to ecancer about the results from the phase II randomised AtezoTRIBE study by GONO. FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.

She begins by talking about how FOLFOXIRI + bev is now recognised as a valuable upfront treatment option, at least for a sub-group of selected mCRC patients and goes into the rationale for further combining the checkpoint inhibitor, atezolizumab.

Dr Cremolini then goes on to talk about the results saying that 218 patients were randomised. A significant advantage by the addition of atezo was observed in PFS, but not in objective response rate. No safety issues were evident.

She concludes by explaining that a mature follow-up is needed to determine overall survival, as only 28% of survival events have been recorded.

Translational analyses to identify predictive biomarkers are ongoing.